HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

SCH 47112

structure in first source

Also Known As:

SCH-47112

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Du, Zhiyong: 1 article (01/2022)
2.	Jin, Ruixia: 1 article (01/2022)
3.	Li, Qimeng: 1 article (01/2022)
4.	Liu, Yifeng: 1 article (01/2022)
5.	Wang, Xianfang: 1 article (01/2022)

Related Diseases

1.	Skin Diseases (Skin Disease) 08/01/1997 - "These results indicate that SCH 47112 exhibits biological activity, inhibiting TPA-induced changes in hairless mouse skin in vivo and cultured human keratinocytes in vitro, and suggest that PKC inhibitors may have a therapeutic role in inflammatory skin diseases."
2.	Inflammation (Inflammations) 08/01/1997 - "SCH 47112 (100 nmol) inhibited TPA-induced epidermal, upper dermal and deep dermal inflammation by 71%, 45% and 22%, respectively, at 24 h (n = 3, P < 0.05). " 08/01/1997 - "We investigated the effects of SCH 47112, a novel staurosporine derivative, which interacts with the catalytic domain of PKC, on TPA-induced inflammation and hyperplasia in hairless mouse skin and TPA-induced differentiation in cultured human keratinocytes. " 08/01/1997 - "SCH 47112, a novel staurosporine derivative, inhibits 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and epidermal hyperplasia in hairless mouse skin."
3.	Hyperplasia 08/01/1997 - "TPA-induced epidermal hyperplasia was inhibited by SCH 47112 (400 nmol) by 38% at 48 h (n = 3, P < 0.05). " 08/01/1997 - "We investigated the effects of SCH 47112, a novel staurosporine derivative, which interacts with the catalytic domain of PKC, on TPA-induced inflammation and hyperplasia in hairless mouse skin and TPA-induced differentiation in cultured human keratinocytes. " 08/01/1997 - "SCH 47112, a novel staurosporine derivative, inhibits 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and epidermal hyperplasia in hairless mouse skin."
4.	COVID-19 01/01/2022 - "According to the prediction results of drug-target affinity of SARS-CoV-2 ion channel targets, seven kinds of small molecule drugs acting on five ion channel targets were obtained, namely SCH-47112, Dehydroaltenusin, alternariol 5-o-sulfate, LPA1 antagonist 1, alternariol, butin, and AT-9283.These drugs provide a reference for drug repositioning and precise treatment of COVID-19."

Related Drugs and Biologics

1.	Staurosporine
2.	Ion Channels (Ion Channel)
3.	dehydroaltenusin
4.	butin
5.	alternariol